Crooke RM - Search Results

1

Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index.

Shen W, De Hoyos CL, Migawa MT, Vickers TA, Sun H, Low A, Bell TA 3rd, Rahdar M, Mukhopadhyay S, Hart CE, Bell M, Riney S, Murray SF, Greenlee S, Crooke RM, Liang XH, Seth PP, Crooke ST. Shen W, et al. Among authors: crooke rm. Nat Biotechnol. 2019 Jun;37(6):640-650. doi: 10.1038/s41587-019-0106-2. Epub 2019 Apr 29. Nat Biotechnol. 2019. PMID: 31036929

2

Antisense oligonucleotides targeting translation inhibitory elements in 5' UTRs can selectively increase protein levels.

Liang XH, Sun H, Shen W, Wang S, Yao J, Migawa MT, Bui HH, Damle SS, Riney S, Graham MJ, Crooke RM, Crooke ST. Liang XH, et al. Among authors: crooke st, crooke rm. Nucleic Acids Res. 2017 Sep 19;45(16):9528-9546. doi: 10.1093/nar/gkx632. Nucleic Acids Res. 2017. PMID: 28934489 Free PMC article.

3

Antisense technology: an overview and prospectus.

Crooke ST, Baker BF, Crooke RM, Liang XH. Crooke ST, et al. Among authors: crooke rm. Nat Rev Drug Discov. 2021 Jun;20(6):427-453. doi: 10.1038/s41573-021-00162-z. Epub 2021 Mar 24. Nat Rev Drug Discov. 2021. PMID: 33762737 Review.

4

Characterization of the Activity and Distribution of a 2'-O-Methoxyethyl-Modified Antisense Oligonucleotide in Models of Acute and Chronic Kidney Disease.

Donner AJ, Bell TA, Greenlee S, Graham MJ, Crooke RM. Donner AJ, et al. Among authors: crooke rm. Nucleic Acid Ther. 2018 Oct;28(5):297-306. doi: 10.1089/nat.2018.0723. Epub 2018 Aug 22. Nucleic Acid Ther. 2018. PMID: 30133341

5

Antisense drug discovery and development technology considered in a pharmacological context.

Crooke ST, Liang XH, Crooke RM, Baker BF, Geary RS. Crooke ST, et al. Among authors: crooke rm. Biochem Pharmacol. 2021 Jul;189:114196. doi: 10.1016/j.bcp.2020.114196. Epub 2020 Aug 13. Biochem Pharmacol. 2021. PMID: 32800852 Review.

6

Antisense technology: A review.

Crooke ST, Liang XH, Baker BF, Crooke RM. Crooke ST, et al. Among authors: crooke rm. J Biol Chem. 2021 Jan-Jun;296:100416. doi: 10.1016/j.jbc.2021.100416. Epub 2021 Feb 16. J Biol Chem. 2021. PMID: 33600796 Free PMC article. Review.

7

Antisense oligonucleotide-mediated inhibition of angiopoietin-like protein 3 increases reverse cholesterol transport in mice.

Bell TA 3rd, Liu M, Donner AJ, Lee RG, Mullick AE, Crooke RM. Bell TA 3rd, et al. Among authors: crooke rm. J Lipid Res. 2021;62:100101. doi: 10.1016/j.jlr.2021.100101. Epub 2021 Aug 6. J Lipid Res. 2021. PMID: 34371033 Free PMC article.

8

Comparison of the pharmacological profiles of murine antisense oligonucleotides targeting apolipoprotein B and microsomal triglyceride transfer protein.

Lee RG, Fu W, Graham MJ, Mullick AE, Sipe D, Gattis D, Bell TA, Booten S, Crooke RM. Lee RG, et al. Among authors: crooke rm. J Lipid Res. 2013 Mar;54(3):602-614. doi: 10.1194/jlr.M029215. Epub 2012 Dec 6. J Lipid Res. 2013. PMID: 23220583 Free PMC article.

9

Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr-/- mice.

Bell TA 3rd, Graham MJ, Lee RG, Mullick AE, Fu W, Norris D, Crooke RM. Bell TA 3rd, et al. Among authors: crooke rm. J Lipid Res. 2013 Oct;54(10):2647-57. doi: 10.1194/jlr.M036509. Epub 2013 Jun 25. J Lipid Res. 2013. PMID: 23801661 Free PMC article.

10

Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice.

Graham MJ, Lemonidis KM, Whipple CP, Subramaniam A, Monia BP, Crooke ST, Crooke RM. Graham MJ, et al. Among authors: crooke st, crooke rm. J Lipid Res. 2007 Apr;48(4):763-7. doi: 10.1194/jlr.C600025-JLR200. Epub 2007 Jan 22. J Lipid Res. 2007. PMID: 17242417 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

100 results

Search Page